Cybin D/B/A Helus Pharma (HELP)

Cybin D/B/A Helus Pharma is trading at $10.77, down 1.55% on the session. The 50 day average sits at $12.12 and the 200 day at $7.59, which puts the stock in a uptrend. RSI is at 45.4, which reads as neutral, and MACD is bearish crossover. Volume is volume spike.

The nearest support is around $9.97 with resistance near $11.62, so that band frames the current range. Average daily movement is roughly $0.90, or about 8.3% of the share price, which is what any stop placement has to allow for. The overall health score of 46 out of 100 combines a trend score of 64, momentum of 36 and a risk score of 30.

Helus Pharma Inc. operates as a clinical stage pharmaceutical company that focuses on developing therapies to treat psychiatric and neurological conditions. It develops HLP003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder; and HLP004, a deuterated N, N-dimethyltryptamine, which is in phase 2 clinical trial for treating generalized anxiety disorders. The company's preclinical product includes HLP005, a phenethylamine and tryptamine derivative to treat central nervous system. It has a strategic partnership agreement with Segal Trials to evaluate HLP003 for the adjunctive treatment of major depressive disorder; and Osmind for mental health treatments. It operates in Canada, the United States, the United Kingdom, and Ireland. The company was formerly known as Cybin Inc. and changed its name to Helus Pharma Inc. in October 2026. Helus Pharma Inc. was founded in 2019 and is headquartered in Toronto, Canada.